{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-056934","form_type":"8-K","ticker":"SPRY","cik":"0001671858","company_name":"ARS Pharmaceuticals, Inc.","filed_at":"2024-05-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.512390+00:00","generated_at":"2026-06-02T06:20:57.426054+00:00","sec_items":["2.02","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"ARS Pharma reports Q1 net loss $10.3M; neffy PDUFA date Oct 2, 2024; cash $223.6M","bullets":["Cash and securities $223.6M as of March 31, 2024; expected operating runway at least three years.","Net loss $10.3M for Q1 2024 compared to $15.0M in Q1 2023; R&D expenses $5.2M, G&A $8.0M.","FDA PDUFA target date for neffy NDA is October 2, 2024; CRL response submitted April 2.","European CHMP opinion on neffy MAA expected in Q2 2024; Day 180 response submitted April 30.","Exclusive license agreement with CSL Seqirus for Australia and New Zealand; up to $5M in payments."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-056934","json":"https://secwatch.observer/filing/0000950170-24-056934.json","markdown":"https://secwatch.observer/filing/0000950170-24-056934.md","text":"https://secwatch.observer/filing/0000950170-24-056934.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1671858/000095017024056934/0000950170-24-056934-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1671858/000095017024056934/spry-20240509.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T06:20:57.426054+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"f4b09de1da0817776fbf9901b180ed41962a283b","claim":"ARS Pharmaceuticals, Inc. reported financial results for the quarter ended March 31, 2024.","evidence_excerpt":"On May 9, 2024, ARS Pharmaceuticals, Inc. (the “Company”) announced its financial results for the quarter ended March 31, 2024 in the press release attached hereto as Exhibit 99.1 and incorporated herein by reference.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1671858/000095017024056934/0000950170-24-056934-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended March 31, 2024"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}